Peginterferon beta-1a - Biogen

Drug Profile

Peginterferon beta-1a - Biogen

Alternative Names: BIIB 017; PEG-interferon-β-1a; PEGylated INF-beta-1a - Biogen; Plegridy

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Interferons
  • Mechanism of Action Immunomodulators; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis

Most Recent Events

  • 14 Sep 2016 Efficacy data from a pooled analysis of phase III trials ATTAIN and ADVANCE in Multiple sclerosis presented by Biogen at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
  • 01 Oct 2015 Registered for Multiple sclerosis in Switzerland (SC)
  • 21 Aug 2015 Biogen has patent protection for peginterferon beta-1a in USA and EU (Biogen 10-K, August 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top